The FDA has approved Rapiblyk, a new drug to treat irregular heartbeats in critically ill hospitalized patients with severe ...

The approval was based on data from 5 randomized, double-blind, placebo-controlled trials that included 317 patients with supraventricular tachycardia.

VIENNA--AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug ...

U.S. FDA Approves AOP Health’s Rapiblyk™ (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting ...